This phenomenon is very likely to be common in autoimmune diseases, suggesting that SHP2 may become a promising common therapeutic target in the treatment of autoimmune diseases by interfering with the differentiation of Treg. This evidence concerns the gene PTPN11 and autoimmune disease.